IS7378A - Lyfjasamsetningar sem samanstanda af 2-(4-etoxý-fenýl)-3-(4-metansúl-fónýl-fenýl)-pýrasóló 1,5-bípýridasín á nanóagna formi - Google Patents

Lyfjasamsetningar sem samanstanda af 2-(4-etoxý-fenýl)-3-(4-metansúl-fónýl-fenýl)-pýrasóló 1,5-bípýridasín á nanóagna formi

Info

Publication number
IS7378A
IS7378A IS7378A IS7378A IS7378A IS 7378 A IS7378 A IS 7378A IS 7378 A IS7378 A IS 7378A IS 7378 A IS7378 A IS 7378A IS 7378 A IS7378 A IS 7378A
Authority
IS
Iceland
Prior art keywords
phenyl
bipyridazine
methanesulphonyl
pyrazolo
ethoxy
Prior art date
Application number
IS7378A
Other languages
English (en)
Inventor
Appleby Jonathan
Rolfe Hill Martin
Joseph Holland Simon
Lynn Pearson Stephanie
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of IS7378A publication Critical patent/IS7378A/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IS7378A 2002-03-15 2004-07-29 Lyfjasamsetningar sem samanstanda af 2-(4-etoxý-fenýl)-3-(4-metansúl-fónýl-fenýl)-pýrasóló 1,5-bípýridasín á nanóagna formi IS7378A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0206200.8A GB0206200D0 (en) 2002-03-15 2002-03-15 Pharmaceutical compositions
PCT/EP2003/002698 WO2003077920A1 (en) 2002-03-15 2003-03-13 Pharmaceutical compositions comprising 2-(4-ethoxy-phenyl)-3-(4-methanesulfonyl-phenyl)-pyrazolo’1,5-bipyridazine in nanoparticulate form

Publications (1)

Publication Number Publication Date
IS7378A true IS7378A (is) 2004-07-29

Family

ID=9933079

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7378A IS7378A (is) 2002-03-15 2004-07-29 Lyfjasamsetningar sem samanstanda af 2-(4-etoxý-fenýl)-3-(4-metansúl-fónýl-fenýl)-pýrasóló 1,5-bípýridasín á nanóagna formi

Country Status (21)

Country Link
US (1) US20050153967A1 (is)
EP (1) EP1485098B1 (is)
JP (1) JP2005520824A (is)
KR (1) KR20040091133A (is)
CN (1) CN1642549A (is)
AT (1) ATE350038T1 (is)
AU (1) AU2003208709A1 (is)
BR (1) BR0307427A (is)
CA (1) CA2478758A1 (is)
DE (1) DE60310896T2 (is)
EA (1) EA007201B1 (is)
EC (1) ECSP045295A (is)
ES (1) ES2277634T3 (is)
GB (2) GB0206200D0 (is)
IS (1) IS7378A (is)
MX (1) MXPA04009008A (is)
NO (1) NO20043889L (is)
NZ (1) NZ534179A (is)
PL (1) PL372932A1 (is)
WO (1) WO2003077920A1 (is)
ZA (1) ZA200406553B (is)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60305053T2 (de) 2002-08-19 2006-08-31 Glaxo Group Ltd., Greenford Pyrimidinderivate als selektive cox-2-inhibitoren
GB0221443D0 (en) 2002-09-16 2002-10-23 Glaxo Group Ltd Pyridine derivates

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
ATE281458T1 (de) * 1997-09-05 2004-11-15 Glaxo Group Ltd Pharmazeutische zusammensetzung, enthaltend 2,3- diaryl-pyrazolo(1,5-b)pyridazin derivate
CO5261556A1 (es) * 1999-12-08 2003-03-31 Pharmacia Corp Composiciones inhibidoras de ciclooxigenasa-2 que tiene rapido acceso de efecto terapeutico
EP1294358B1 (en) * 2000-06-28 2004-08-18 Smithkline Beecham Plc Wet milling process

Also Published As

Publication number Publication date
JP2005520824A (ja) 2005-07-14
KR20040091133A (ko) 2004-10-27
WO2003077920A1 (en) 2003-09-25
EA007201B1 (ru) 2006-08-25
US20050153967A1 (en) 2005-07-14
DE60310896T2 (de) 2007-05-10
NZ534179A (en) 2006-07-28
GB2402335B (en) 2005-10-12
ATE350038T1 (de) 2007-01-15
GB2402335A (en) 2004-12-08
BR0307427A (pt) 2004-12-28
CA2478758A1 (en) 2003-09-25
ES2277634T3 (es) 2007-07-16
DE60310896D1 (de) 2007-02-15
ECSP045295A (es) 2004-10-26
CN1642549A (zh) 2005-07-20
AU2003208709A1 (en) 2003-09-29
EP1485098A1 (en) 2004-12-15
GB0206200D0 (en) 2002-05-01
MXPA04009008A (es) 2004-12-07
NO20043889L (no) 2004-09-16
EA200400864A1 (ru) 2005-02-24
GB0419971D0 (en) 2004-10-13
PL372932A1 (en) 2005-08-08
EP1485098B1 (en) 2007-01-03
ZA200406553B (en) 2005-09-22

Similar Documents

Publication Publication Date Title
EA200500853A1 (ru) 2,4,6-тризамещённые пиримидины, являющиеся ингибиторами фосфотидилинозитол(pi)-3-киназы, и их применение при лечении рака
MXPA04002167A (es) Inhibidores de la 17 beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades androgeno-dependientes.
WO2002057252A3 (en) Heterocyclic sulfonamide inhibitors of beta amyloid production
GEP20064005B (en) Use of novel benzoimidazole derivatives as antiproliferative agents
BG108269A (en) Pyrazolopyrimidines as therapeutic agents
BG106586A (en) Pyrazolopyramidines as therapeutic agents
BRPI0114870B8 (pt) uso de 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il)pirimidin-2-amino)fenil]-benzamida para a fabricação de composições farmacêuticas para tratamento de tumores estromais gastrointestinais
TR200200579T2 (tr) Amino-tirazolpiridin türevleri.
DE60142891D1 (de) Azetidinderivate enthaltende pharmazeutische zusammensetzungen, die azetidinderivate und deren herstellung
ES2421948T3 (es) Compuestos y composiciones para suministrar agentes activos
NO20044767L (no) Farmasoytisk formulering med modifisert frigjoring
SE9803518D0 (sv) Novel compounds
ATE303384T1 (de) 1-biaryl-1,8-naphthyridin-4-one als phosphodieseterase-inhibitoren
UY27979A1 (es) Indoles sustituidos en posición 2,4
WO2003053971A8 (en) Pyridoquinoxaline antivirals
EA200200876A1 (ru) Алкилированные производные имидазопиридина
HK1053833A1 (zh) 取代苯基法呢基转移酶抑制剂
GEP20074058B (en) 4-(7-halo-2-quino(xa) linyloxy-phenoxy-propionic acid derivatives as antineoplastic agents
DK1109560T3 (da) Som AICARFT-inhibitorer anvendelige forbindelser
WO2004000793A3 (en) Aminoacetonitrile derivatives suitable for controlling parasites
HRP20010885B1 (en) Ethanesulfonyl-piperidine derivatives
NO20043889L (no) Farmasoytiske blandinger omfattende 2-(4-etoksy-fenyl)-3-(4-metansulfonyl-fenyl)-pyrazolo' 1,5-bipyridazin i nanopartikkelform
SE0102641D0 (sv) Novel compounds
DE60103034D1 (de) Neue phenylheteroalkylamin-derivate
EA200400877A1 (ru) 2'-гало-3',5'-диалкоксифен-1'-илимино-2-имидазолидиновые производные и их применение для лечения недержания мочи